title: Augmented behavioral response and enhanced synaptosomal calcium transport induced by repeated cocaine administration are decreased by calcium channel blockers.
abstract: Recent studies suggest that calcium influx via L-type calcium channels is necessary for psychostimulant-induced behavioral sensitization. In addition, chronic amphetamine upregulates subtype Cav1.2-containing L-type calcium channels. In the present studies, we assessed the effect of calcium channel blockers (CCBs) on cocaine-induced behavioral sensitization and determined whether the functional activity of L-type calcium channels is altered after repeated cocaine administration. Rats were administered daily intraperitoneal injections of either flunarizine (40 mg/kg), diltiazem (40 mg/kg) or cocaine (20 mg/kg) and the combination of the CCBs and cocaine for 30 days. Motor activities were monitored on Day 1, and every 6th day during the 30-day treatment period. Daily cocaine administration produced increased locomotor activity. Maximal augmentation of behavioral response to repeated cocaine administration was observed on Day 18. Flunarizine pretreatment abolished the augmented behavioral response to repeated cocaine administration while diltiazem was less effective. Measurement of tissue monoamine levels on Day 18 revealed cocaine-induced increases in DA and 5-HT in the nucleus accumbens. By contrast to behavioral response, diltiazem was more effective in attenuating increases in monoamine levels than flunarizine. Cocaine administration for 18 days produced increases in calcium uptake in synaptosomes prepared from the nucleus accumbens and frontal cortex. Increases in calcium uptake were abolished by flunarizine and diltiazem pretreatment. Taken together, the augmented cocaine-induced behavioral response on Day 18 may be due to increased calcium uptake in the nucleus accumbens leading to increased dopamine (DA) and serotonin (5-HT) release. Flunarizine and diltiazem attenuated the behavioral response by decreasing calcium uptake and decreasing neurochemical release.
authors: Department of Pharmacology, Meharry Medical College, Nashville, TN 37208, USA.
authors: K
authors: K
authors: Mills
authors: T A
authors: TA
authors: Ansah
authors: S F
authors: SF
authors: Ali
authors: S
authors: S
authors: Mukherjee
authors: D C
authors: DC
authors: Shockley
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D015306:Biogenic Monoamines / Q000378:metabolism; D001693:Biological Transport, Active; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D020746:Calcium Channels, L-Type / Q000187:drug effects / Q000502:physiology; D002132:Calcium Radioisotopes; D002421:Caudate Nucleus / Q000187:drug effects / Q000378:metabolism; D003042:Cocaine / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D004110:Diltiazem / Q000494:pharmacology; D005444:Flunarizine / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism*
chemical_list: D015306:Biogenic Monoamines; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D002132:Calcium Radioisotopes; D004110:Diltiazem; D003042:Cocaine; D005444:Flunarizine; D002118:Calcium
references: Neuropsychopharmacology. 1999 Jun;20(6):591-602
references: 10327428
references: Brain Res. 1999 Jul 3;833(2):133-41
references: 10375688
references: Eur J Pharmacol. 1999 Jul 9;376(3):207-15
references: 10448878
references: Psychopharmacology (Berl). 2000 Sep;152(1):110-8
references: 11041323
references: Addiction. 2001 Jan;96(1):103-14
references: 11177523
references: Psychopharmacology (Berl). 2001 May;155(3):221-9
references: 11432683
references: J Neurochem. 2002 Apr;81(2):292-300
references: 12064476
references: Annu Rev Psychol. 2003;54:25-53
references: 12185211
references: Pharmacol Biochem Behav. 2002 Nov;73(4):877-82
references: 12213534
references: J Neurochem. 2003 Apr;85(1):14-22
references: 12641723
references: Neurochem Int. 1992 Jul;21(1):99-107
references: 1303146
references: Cell Calcium. 1992 Nov;13(10):659-67
references: 1337502
references: Pharmacol Biochem Behav. 1992 Dec;43(4):1023-31
references: 1361988
references: J Neurosci. 2003 Nov 12;23(32):10265-73
references: 14614085
references: J Biol Chem. 1951 Nov;193(1):265-75
references: 14907713
references: J Neurosci. 2004 Aug 25;24(34):7464-76
references: 15329393
references: Pharmacol Biochem Behav. 1992 Mar;41(3):497-500
references: 1533936
references: Life Sci. 2006 Aug 1;79(10):981-90
references: 16765386
references: Brain Res Bull. 1991 Mar;26(3):445-7
references: 1828708
references: Life Sci. 1991;49(2):165-70
references: 2062172
references: Eur J Pharmacol. 1990 Nov 6;190(1-2):217-21
references: 2076753
references: Eur J Pharmacol. 1990 Nov 6;190(1-2):223-7
references: 2076754
references: Circ Res. 1990 Aug;67(2):469-80
references: 2165445
references: Life Sci. 1990;46(9):635-45
references: 2308472
references: Eur J Pharmacol. 1990 Feb 6;176(2):245-6
references: 2311670
references: J Physiol. 1975 Jun;247(3):617-55
references: 238033
references: Biochem Pharmacol. 1986 Jul 1;35(13):2193-7
references: 2425811
references: Biochemistry. 1988 Jul 12;27(14):5275-81
references: 2458759
references: Eur J Pharmacol. 1989 Jul 18;166(2):261-9
references: 2477260
references: J Neurosci. 1985 Mar;5(3):841-9
references: 2579220
references: Ann N Y Acad Sci. 1998 May;844(1):201-207
references: 29090812
references: Brain Res. 1985 Mar 25;330(2):217-23
references: 2985193
references: Brain Res. 1981 Dec 7;226(1-2):107-18
references: 7296283
references: J Neurosci. 1995 Sep;15(9):6287-99
references: 7666211
references: J Pharmacol Exp Ther. 1995 Feb;272(2):791-8
references: 7853196
references: Psychopharmacology (Berl). 1994 Jan;113(3-4):378-80
references: 7862848
references: Psychopharmacology (Berl). 1994 Jan;113(3-4):404-10
references: 7862852
references: Life Sci. 1995;56(7):475-83
references: 7869827
references: Pharmacol Biochem Behav. 1994 Apr;47(4):973-9
references: 8029272
references: Pharmacol Biochem Behav. 1993 Mar;44(3):661-4
references: 8095726
references: Life Sci. 1993;53(26):1947-56
references: 8255157
references: Pharmacol Biochem Behav. 1993 Nov;46(3):715-22
references: 8278450
references: Mol Neurobiol. 1995 Aug-Dec;11(1-3):31-46
references: 8561966
references: J Physiol Pharmacol. 1996 Sep;47(3):497-502
references: 8877905
references: Physiol Behav. 1996 Nov;60(5):1261-7
references: 8916180
references: Brain Res. 1996 Oct 21;737(1-2):215-20
references: 8930368
references: Life Sci. 1997;60(8):PL119-26
references: 9042392
references: J Neurosci. 1997 May 1;17(9):3254-61
references: 9096158
references: J Pharmacol Exp Ther. 1997 Aug;282(2):521-7
references: 9262311
references: Pharmacol Biochem Behav. 1997 Dec;58(4):1117-22
references: 9408222
references: Pharmacology. 1997 Dec;55(6):292-8
references: 9413858
references: Nature. 1976 Apr 22;260(5553):731-2
references: 944382
references: J Pharmacol Exp Ther. 1998 Apr;285(1):277-84
references: 9536022
references: Eur J Pharmacol. 1998 Jan 26;342(2-3):339-45
references: 9548406
references: J Psychopharmacol. 1998;12(1):49-53
references: 9584968
references: Synapse. 1998 Jun;29(2):148-61
references: 9593105
references: Am J Psychiatry. 1998 Jun;155(6):832-4
references: 9619159
references: Drug Alcohol Depend. 1998 Jun-Jul;51(1-2):87-96
references: 9716932
references: Pharmacol Biochem Behav. 1998 Oct;61(2):181-92
references: 9738534